Oncolytic viruses for triple negative breast cancer and beyond.
Oncolytic viruses for triple negative breast cancer and beyond.
复制标题
用于三阴性乳腺癌及其他癌症的溶瘤病毒
DOI：
10.1186/s40364-021-00318-4
复制
发表时间：
2021-09-25
影响因子：
11.1
通讯作者：
Xu S
中科院分区：
文献类型：
--
作者：
Jin S;Wang Q;Wu H;Pang D;Xu S
生物疗法被认为是一种替代疗法，能够像手术、放疗和化疗一样对肿瘤产生同样的效果。溶瘤病毒（OVs）作为生物治疗领域的重要组成部分，受到了广泛的关注并取得了良好的效果。具体而言，OVs在头颈癌和黑色素瘤中的成功应用，促进了其在三阴性乳腺癌（TNBC）中的研究。TNBC是一种高危分子型乳腺癌，具有侵袭性强、易复发、转移等特点。由于缺乏雌激素和孕激素受体，以及缺乏人表皮生长因子受体2 （HER2）的过表达或基因扩增，内分泌治疗和抗HER-2靶向治疗已被证明无效。虽然化疗在部分TNBC患者中已显示出可观的疗效，但耐药和预后不良的发生促使人们探索新的有效治疗方法。OVs的出现为TNBC的治疗提供了一个新的平台。事实上，一些研究已经证实了OVs在TNBC中的治疗作用。大量研究也调查了OVs在其他恶性肿瘤中的疗效，包括实体瘤临床试验，从而进一步证明了溶瘤病毒治疗在TNBC中的应用前景广阔。本综述的主要重点是研究OVs抗肿瘤特性的机制，同时总结OVs在TNBC治疗方面的研究进展，以及由OVs和其他疗法组成的各种组合策略。我们还简要介绍了具体的相关临床试验，并讨论了新型OVs治疗其他恶性肿瘤的一些研究进展，从而肯定了OVs治疗TNBC以及其他癌症的巨大治疗潜力。
Biological therapy is considered an alternative treatment capable of eliciting the same effects on tumors as surgery, radiotherapy, and chemotherapy. As a major player in biological therapy, oncolytic viruses (OVs) have attracted great attention and achieved good results. Specifically, the successful application of OVs in head and neck cancer, as well as melanoma, promoted its research in triple negative breast cancer (TNBC). TNBC is a high-risk molecular type of breast cancer, characterized by strong invasion, easy recurrence, and metastasis. Due to the absence of estrogen and progesterone receptors, as well as the absence of overexpression or gene amplification of human epidermal growth factor receptor 2 (HER2), endocrine therapy and anti HER-2 targeted therapy have proven ineffective. Although chemotherapy has shown substantial efficacy in some TNBC patients, the occurrence of drug resistance and poor prognosis have prompted the exploration of new and effective treatment methods. The emerging concept of OVs provides a new platform to treat TNBC. Indeed, several studies have confirmed the therapeutic effects of OVs in TNBC. Numerous studies have also investigated the efficacy of OVs in other malignances, including solid tumor clinical trials, thus further demonstrating the promising application of oncolytic virotherapy for TNBC. The primary focus of the current review is the examination of OV mechanisms underlying their antitumor properties, while also summarizing the ongoing progress in OV research regarding TNBC treatment, as well as the various combinatorial strategies comprising OVs and other therapies. We also briefly introduce specific relevant clinical trials and discuss some of the progress in the research of novel OVs for the treatment of other malignancies, thereby affirming the significant therapeutic potential of OVs for the treatment of TNBC, as well as other cancers.
登录
查看更多内容
影响因子：
6.5
作者：
Au, Gough G.;Lincz, Lisa F.;Shafren, Darren R.
通讯作者：
Shafren, Darren R.
影响因子：
2.9
作者：
Cheng L;Jiang H;Fan J;Wang J;Hu P;Ruan Y;Liu R
通讯作者：
Liu R
影响因子：
4.6
作者：
Balachandran, S;Barber, GN
通讯作者：
Barber, GN
影响因子：
3.7
作者：
Bergman, I;Whitaker-Dowling, P;Griffin, JA
通讯作者：
Griffin, JA
影响因子：
12.4
作者：
Breitbach, Caroline J.;Paterson, Jennifer M.;Bell, John C.
通讯作者：
Bell, John C.